The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback